Rti Biologics, Inc. (RTIX) Tops Q4 EPS by 1c

Rti Biologics, Inc. (NASDAQ: RTIX) reported Q4 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $70.9 million versus the consensus estimate of $65.02 million.

Rti Biologics, Inc. sees FY2015 EPS of $0.17-$0.22, versus the consensus of $0.17. Rti Biologics, Inc. sees FY2015 revenue of $278-285 million, versus the consensus of $278.5 million.

For earnings history and earnings-related data on Rti Biologics, Inc. (RTIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Diana Shipping withdraws bid to acquire Genco Shipping